Anyone who smokes and/or has shortness of breath and sputum production could have COPD

Similar documents
6- Lung Volumes and Pulmonary Function Tests

PULMONARY FUNCTION TESTING. Purposes of Pulmonary Tests. General Categories of Lung Diseases. Types of PF Tests

PULMONARY FUNCTION TESTS

Teacher : Dorota Marczuk Krynicka, MD., PhD. Coll. Anatomicum, Święcicki Street no. 6, Dept. of Physiology

Physiology lab (RS) First : Spirometry. ** Objectives :-

COPD. Helen Suen & Lexi Smith

What do pulmonary function tests tell you?

Spirometry in primary care

People with asthma who smoke. The combination of asthma, a chronic airway disease, and smoking increases the risk of COPD even more.

Chronic Obstructive Pulmonary Disease (COPD) Clinical Guideline

S P I R O M E T R Y. Objectives. Objectives 3/12/2018

Chronic Obstructive Pulmonary Disease A breathtaking condition

COPD. Breathing Made Easier

S P I R O M E T R Y. Objectives. Objectives 2/5/2019

RESPIRATORY PHYSIOLOGY Pre-Lab Guide

Lung function testing

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters

PULMONARY FUNCTION. VOLUMES AND CAPACITIES

The following Resources provide surveys, checklists and information for quick reference and better understanding of COPD.

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

LEARNING OBJECTIVES FOR COPD EDUCATORS

Sample blf.org.uk/copd

COPD. Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS

COPD Treatable. Preventable.

SPIROMETRY TECHNIQUE. Jim Reid New Zealand

Pulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?

Chronic Obstructive Pulmonary Disease

Reference Guide for Group Education

Chronic Obstructive Pulmonary Disease. Information about medication and an Action Plan to use if your condition gets worse due to an infection

SPIROMETRY. Marijke Currie (CRFS) Care Medical Ltd Phone: Copyright CARE Medical ltd

THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable

How to treat COPD? What is the mechanism of dyspnea? Smoking cessation

PFT Interpretation and Reference Values

Living well with COPD

MSRC AIR Course Karla Stoermer Grossman, MSA, BSN, RN, AE-C

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES

Chronic obstructive pulmonary disease

Chronic obstructive lung disease. Dr/Rehab F.Gwada

A patient educational resource provided by Boehringer Ingelheim Pharmaceuticals, Inc.

Understanding and Managing Your Chronic Obstructive Pulmonary Disease (COPD)* *Includes chronic bronchitis and emphysema.

written by Harvard Medical School COPD It Can Take Your Breath Away

Spirometry: an essential clinical measurement

Chronic Obstructive Learning Collaborative Sponsored by AMGA and Boehringer Ingelheim Pharmaceuticals, Inc.

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?

Running head: BEST-PRACTICE NURSING CARE FOR PATIENTS WITH 1 CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Self-management plan for COPD

COPD: Current Medical Therapy

Chronic Obstructive Pulmonary Disease Guidelines and updates

UNDERSTANDING & MANAGING

Breathing and pulmonary function

Chapter 3. Pulmonary Function Study Assessments. Mosby items and derived items 2011, 2006 by Mosby, Inc., an affiliate of Elsevier Inc.

COPD COPD. C - Chronic O - Obstructive P - Pulmonary D - Disease OBJECTIVES

Overview of COPD INTRODUCTION

Analysis of Lung Function

COPD. The goals of COPD. about. you quit. If you. efforts to quit. Heart

Spirometry: Introduction

Coexistence of confirmed obstruction in spirometry and restriction in body plethysmography, e.g.: COPD + pulmonary fibrosis

Spirometry. Obstruction. By Helen Grim M.S. RRT. loop will have concave appearance. Flows decreased consistent with degree of obstruction.

MANAGING COPD AT HOME. Karla Schlichtmann, RRT

Pulmonary Function Testing The Basics of Interpretation

Chronic Obstructive Pulmonary Disease (COPD)

Treatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1

Get Healthy Stay Healthy

Online Data Supplement. Prevalence of Chronic Obstructive Pulmonary Disease in Korea: Results of a Population-based Spirometry Survey

Understanding the Basics of Spirometry It s not just about yelling blow

VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide

Asthma. & Older Adults. A guide to living with asthma for people aged 65 years and over FOR PATIENTS & CARERS

UNIT TWO: OVERVIEW OF SPIROMETRY. A. Definition of Spirometry

Patient assessment - spirometry

Referring for specialist respiratory input. Dr Melissa Heightman Consultant respiratory physician, UCLH,WH, CNWL

Getting Spirometry Right It Matters! Performance, Quality Assessment, and Interpretation. Susan Blonshine RRT, RPFT, AE-C, FAARC

Differential diagnosis

Pulmonary Function Tests. Mohammad Babai M.D Occupational Medicine Specialist

SCREENING AND PREVENTION

A Patient s Guide to Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease, shortened to COPD, is an umbrella term for a group of conditions which cause long-term damage to the airways.

Pulmonary Function Testing

COPD in primary care: reminder and update

Chronic Obstructive Pulmonary Disease

Known Allergies: Shellfish. Symptoms: abdominal pain, nausea, diarrhea, or vomiting. congestion, trouble breathing, or wheezing.

COPD: Applying New Guidelines to Optimizing Evaluation and Treatment

TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS

Basic approach to PFT interpretation. Dr. Giulio Dominelli BSc, MD, FRCPC Kelowna Respiratory and Allergy Clinic

COPD. Definitionn. make. when (bronchioles) in. the lungs. Wheezing Chest tightness. your lungs. greenish. Lack of energy

Office Based Spirometry

COPD Journal Patient Name

Asthma and COPD Awareness

The Respiratory System

WHEN COPD* SYMPTOMS GET WORSE

Center for Respiratory and Sleep Medicine COPD Chronic Disease Management Program

GINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017

Respiratory Physiology In-Lab Guide

CARE OF THE ADULT COPD PATIENT

Spirometry: FEVER DISEASE DIABETES HOW RELIABLE IS THIS? 9/2/2010 BUT WHAT WE PRACTICE: Spirometers are objective tools

Healthy Lungs. Presented by: Brandi Bishop, RN and Patty Decker, RRT, RCP

Clinical Practice Guideline: Asthma

Care Bundle. Adult patients with COPD

Tobacco Cessation Toolkit

CLINICAL PATHWAY. Acute Medicine. Chronic Obstructive Pulmonary Disease

Transcription:

COPD DIAGNOSIS AND MANAGEMENT CHECKLIST Anyone who smokes and/or has shortness of breath and sputum production could have COPD Confirm Diagnosis Presence and history of symptoms: Shortness of breath Cough Sputum production Smoking history and willingness to quit: Smoker Willingness to quit:high medium low Previous smoker Non-smoker Other smoking-related disease Occupational Exposures: Yes No Spirometry: Measure FEV1 and FEV1 /FVC COPD is defined as post-bronchodilator FEV1 /FVC <70% and FEV1 <80% predicted. Assess reversibility of airflow limitation Reversibility is defined as > 12% improvement in FEV1 and at least a 200ml increase post Bronchodilator. If fully reversible (to normal values) treat as asthma. Stages of COPD FEV1 % of predicted post-bronchodilator Stage I - >80% = Mild Stage II - <80% = Moderate Stage III - <50% = Severe Stage IV - <30% = Very Severe If FEV1 <50% predicted plus chronic respiratory failure, patient may have very severe Stage IV COPD even if the FEV 1 is >30% predicted whenever this complication is present. Optimize Health Review appropriate medication use Discuss barriers to adherence Review exercise status; encourage activity Check current device use Discuss nutrition Consider education/pulmonary rehab Consider referral to specialist Prevent Deterioration Essential steps Annual influenza vaccination Pneumococcal vaccination Long-term home oxygen as indicated Risk factor reduction Check current smoking status Determine home exposure to environmental tobacco smoke Advise of risks of smoking and benefits of stopping Refer to California Smokers Helpline (800)662-8887 or (800)844-CHEW Advise about pharmacological treatments for nicotine dependence Address occupational exposures Develop Self-management Plan and Action Plan Assist in the development of self-management and action plans Schedule follow up visit Ensure understanding of exacerbations, importance of early action and treatment at home if possible Adapted from Maine Health COPD Program 09/2017

COPD FLOW SHEET To prompt Tobacco/COPD status assessment and delivery of assistance Patient ID: Patient Name: Date: DOB: Gender: Alpha 1 antitrypsin measure: Tobacco Status Tobacco Type (all that apply) ETS Exposure Currently using tobacco Cigarette # in household: Quit <12 mos. ago. Not smoking now Cigar/Pipe Quit 12 mos. ago. Not smoking now Smokeless Never smoked amount/day Tobacco History Age began: # of quit attempts: Quit attempts (Dates, successes, challenges, etc.): Visit Date: IMMUNIZATIONS Influenza Pneumococcal TOBACCO: Assess and Assist Status (each visit) Assist (brief counsel, medication each visit) Helpline (provide resources) LABS FEV 1 (pre/post as indicated) COPD Stage (per spirometry) SELF MANAGEMENT SUPPORT AND PATIENT EDUCATION Self Management goal setting (annual) Date: Education session or referral Date: Pulmonary Rehab referral Date Better Breathers referral Date: GOLD Therapy at Each Stage of COPD I: Mild II: Moderate III: Severe IV: Very Severe FEV 1 /FVC <70% FEV 1 80% predicted FEV 1 /FVC <70% 50% FEV 1 <80% predicted FEV 1 /FVC <70% 30% FEV 1 50% predicted FEV 1 /FVC <70% FEV 1 <30% predicted or FEV 1 <50% predicted plus chronic respiratory failure Active reduction of risk factor(s): influenza vaccination Add short acting bronchodilator (when needed) Add regular treatment with one or more long acting bronchodilators (when needed); Add rehabilitation Add inhaled glucocorticosteriods if repeated exacerbations *GOLD Guidelines to COPD Diagnosis, Management, and Prevention Updated November 2009 11/15/2010 Adapted from Maine Health COPD Program

Chronic Obstructive Pulmonary Disease - COPD ACTION PLAN - Actions for you to take when your symptoms increase Name: Severity Latest FEV 1 Date SYMPTOMS Breathe easily during usual activities Mucus is clear/white, easy to cough up, small in amount Able to think clearly Can do usual activities without getting tired ACTION TO CONTINUE 1. Continue with your usual activities including physical activities 2. Take medicines as ordered by your health care provider WORSENING SYMPTOMS More shortness of breath, wheezing or coughing as usual ACTIONS TO TAKE 1. Take nebulizer treatment or rescue inhaler 2. Use pursed lip breathing and relaxation exercises 3. Pace yourself and limit activities 4. Contact your health care provider/doctor Mucus is thicker or stickier than usual Mucus is green, yellow or brown for more than 12 hours Blood in mucus Fever develops and is above 100.4 1. Increase fluids, if no fluid limit (non-caffeine drinks) 2. Consider medicine to thin mucus 3. Start antibiotic if ordered by your doctor 4. Call your doctor to inform about changes in symptoms More forgetful, restless, less able to concentrate Gained or lost weight for no reason; swelling in feet or ankles Tired and not able to finish usual activities without resting Feels that, in general, health has worsened Difficulty sleeping Morning headaches, dizzy spells or restlessness 1. Contact your doctor: 2. Call a family member, if available SEVERE SYMPTOMS Breathing does not improve with treatment Chest pain Feel like you are going to faint Frightened by not being able to breathe Frightened by how tired or drowsy you feel Confusion ACTIONS TO TAKE 1. Call your doctor NOW Phone #: 2. Call 911 if unable to take to doctor or nurse right away OR go to the nearest (ER) emergency room Medications recommended by your health care provider/doctor Signature Date Adapted from Maine Health COPD Program

This survey asks questions about you, your breathing and what you are able to do. To complete the survey, mark an X in the box that best describes your answer for each question below. 1. During the past 4 weeks, how much of the time did you feel short of breath? None of A little of Some of Most of All of the time the time the time the time the time 0 0 1 2 2 2. Do you ever cough up any stuff, such as mucus or phlegm? Only with No, never occasional colds or chest infections Yes, a few days a month Yes, most days a week Yes, every day 0 0 1 1 2 3. Please select the answer that best describes you in the past 12 months. I do less than I used to because of my breathing problems. Strongly Strongly Disagree Disagree Unsure Agree Agree 0 0 0 1 2 4. Have you smoked at least 100 cigarettes in your ENTIRE LIFE? 5. How old are you? No Yes Don t know 0 2 0 Age 35 to 49 Age 50 to 59 Age 60 to 69 Age 70+ 0 1 2 2 How to score the survey: In the spaces below, write the number that is next to your answer for each of the questions. Add the numbers to get the total score. The total score can range from 0 to 10. + + + + = #1 #2 #3 #4 #5 TOTAL SCORE If your total score is between 0 and 4: Although you may have a low score, if you experience problems with your breathing, please share the results of this survey with your doctor along with your smoking history and breathing problems. Your doctor can help evaluate any type of breathing problem you may have (you may require a breathing test). If your total score is between 5 and 10: You may have breathing problems that could be related to COPD (which includes chronic bronchitis and emphysema). The higher your score, the more likely it is that you have COPD. This is a serious lung disease that gradually gets worse over time. COPD is the 2nd leading cause of disability and 4th leading cause of death in the U.S. Please share the results of this survey with your doctor, who can help evaluate your breathing problems by performing a simple breathing test (known as spirometry) and confirm if you have COPD. The COPD screener you took has been tested and validated in a general population of patients 35 years and older. Copyright 2006, Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved. COPD Population Screener 2004 by QualityMetric Incorporated. All rights reserved. COPD Population Screener is a trademark of QualityMetric Incorporated.

Spirometry Tests A spirometry is a functional test of the lungs. The most important spirometry test is the FVC (Forced Vital Capacity). Other tests include the CV (Vital Capacity or Slow Vital Capacity) and MVV (Maximum Voluntary Ventilation). Forced Vital Capacity The Forced Vital Capacity consists of a forced expiration in the spirometer. The patient either sits or stands. He inspires fully and expires all the air out of the lungs as fast as he can. The results of the test are compared to the predicted values that are calculated from his age, size, weight, sex and ethnic group. Two curves are shown after the test: the flow-volume loop and volume-time curve. The Volume-Time curve explained: The volume expired in the first second of the FVC test is called FEV1 (Forced Expiratory Volume in the first second) and is a very important parameter in spirometry. The FEV1% is the FEV1 divided by the VC (Vital Capacity: see next spirometry test on this page) times 100: FEV1%=FEV1/VC X100. Nowadays FEV1/FVC X100 is also accepted as FEV1%.

A healthy patients expires approximately 80% of all the air out of his lungs in the first second during the FVC maneuver. A patient with an obstruction of the upper airways has a diminished FEV1%. A FEV1% that is too high is suggestive for a restriction of the pulmonary volume. After 6 seconds a second parameter is obtained: FEV6. This is more and more used as an alternative for FVC. FEV1/FEV6 can than be used in stead of FEV1/FVC. The Flow-Volume loop explained: This is the most important curve in spirometry. A normal Flow-Volume loop begins on the X-axis (Volume axis): at the start of the test both flow and volume are equal to zero. Directly after this starting point the curve rapidly mounts to a peak: Peak (Expiratory) Flow. If the test is performed correctly, this PEF is attained within the first 150 milliseconds of the test. The Peak Flow is a measure for the air expired from the large upper airways (trachea-bronchi). After the PEF the curve descends (=the flow diminishes) as more air is expired. After 25% of the total expired volume, the parameter FEF25 is reached. Halfway the curve (when the patient has expired half of the volume) the FEF50 is reached: Forced Expiratory Flow at 50% of the FVC. After 75% the parameter FEF75 is reached. The mean flow between the points FEF25 and FEF 75 is also a very important parameter and is called the FEF2575. This is actually the first parameter that will decline in many respiratory diseases.

It is important to realise that there is no time axis on the flow-volume loop so one can not interpret time intervals. A healthy patient will expire between 70 and 90% of the FVC in the first second of the test. This means that he takes roughly about 5 seconds to expire the last 10 to 30 % of the FVC. The point where the FEV1 is reached is shown on the curve as an illustration. When the flow reaches zero, the FVC is reached (Force Vital Capacity): the patient has blown out as much air as he can. After this it is recommended that the patient makes a complete and forced inspiration (to obtain a closed flow-volume loop), but the test can be interpreted without this as well. The morphology of the flow-volume loop is very important. To the trained eye the flow-volume loop tells immediately if the test was well done. If the flow-volume loop is concave, a bronchial obstruction can be suspected (ie. in the case of COPD). (Slow) Vital Capacity: This test resembles the FVC. The difference is that the expiration in the spirometer is done slowly. The patient inspires fully and than slowly expires all the air in his lungs (Inspiratory Vital Capacity) or the other way around: the patient expires fully and inspires slowly to a maximum (Expiratory Vital Capacity). Even if the patient has expired fully, there is always some air left in the lungs. This is the Residual Volume. The total Lung Capacity is equal to the (F)VC + the Residual Volume. The Residual Volume is about 20-25% of the Lung Capacity. It is impossible to measure the RV with a spirometer. More sophisticated methods like the helium dilution test or body plethysmography are needed to measure the RV. If the VC is different from the FVC a collapse of the small airways is suspected (if both tests were performed correctly).

Maximum Voluntary Ventilation: For this test the patient inspires and expires in the spirometer over and over again as fast as he can, during at least 12 seconds. This is no longer a very common test as it can be dangerous for some people. Sometimes the MVV is still done in athletes.

Partnership HealthPlan of California Pulmonary Rehabilitation Questionnaire Patient s Name: Date: M or F Weight: Height: Age: DOB: Does the patient have severe, stage III COPD, demonstrated by FEV1 of less than 50% of predicted value. Pulmonary Function Testing (PFT) results must be submitted with TAR. Does the patient have decreased quality of life due to problems with control of COPD? Does the patient have worsening pulmonary symptoms? Has maximized pharmaceutical treatment been used? Is the patient no longer smoking cigarettes or at least actively quitting by evidence of use of tobacco cessation product? Is the patient unable to walk more than 300 feet? YES NO I:\POLICIES\MULTI-PROGRAM\UM\MP3111 Pulmonary Rehabilitation Questionnaire (10-20-10).doc